Wednesday, February 10, 2010, 3:06am EST - Canadian Markets open in 6 hours and 24 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Trimeris Inc. (TRMS)

 On Feb 9: 2.35 USD   0.00 (0.00%)  
MORE ON TRMS
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Trimeris, Inc. (NGM:TRMS) Delayed quote dataEdit
Last Trade: 2.35 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 2.35
Open: N/A
Bid: N/A
Ask: N/A
1y Target Est: 6.00
Day's Range: N/A - N/A
52wk Range: 1.01 - 3.68
Volume: 0
Avg Vol (3m): 202,513
Market Cap: 52.52M
P/E (ttm): 2.24
EPS (ttm): 1.05
Div & Yield: N/A (N/A%)
Trimeris Inc. (TRMS)
1d  5d  3m  6m  1y  2y  5y  max 
 Add TRMS to Portfolio   Download Data

HEADLINES
• TRIMERIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Wed, Feb 3)
• Trimeris Reports Fourth Quarter 2009 FUZEON® Sales Results
Business Wire (Tue, Feb 2)
• TRIMERIS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tran
EDGAR Online (Mon, Jan 11)
• Trimeris Receives Delisting Notice From NASDAQ
Business Wire (Mon, Jan 11)
• CSI: Trimeris-Arigene
at The New York Times (Mon, Jan 11)
• TRIMERIS INC Files SEC form 8-K, Termination of a Material Definitive Agreement
EDGAR Online (Tue, Jan 5)
• Pfizer Discontinues Cancer Drug: Biotech's Recently Missed Targets
at Seeking Alpha (Mon, Jan 4)
• TRIMERIS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Tue, Dec 29)
• CBL & Associates Properties, Trimeris: Biggest Price Decliners (CBL, TRMS)
at The Wall Street Journal Online (Tue, Dec 29)
• Biotech Stocks: Drug stocks slip; Trimeris falls on failed merger
at MarketWatch (Tue, Dec 29)
• Korean medical product maker ends bid for Trimeris
AP (Tue, Dec 29)
More Headlines for TRMS...
ANALYST
EPS Est (next year) (Dec-07) : 0.96
EPS Est (in 2 years) (Dec-08) : 0.98
Avg Rec (current)*: 3.4
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Trimeris, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic agents for the treatment of viral disease in the United States and Canada.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices